Here, we report the identification of the RNA Binding Motif protein RBM15B/OTT3 as a new CDK11 p110 binding partner that alters the effects of CDK11 on splicing. RBM15B was initially identified as a binding partner of the Epstein-Barr virus mRNA export factor and, more recently, as a co-factor of the nuclear export receptor NXF1. In this study, we found that RBM15B co-elutes with CDK11 p110 , cyclin L2 and SR proteins, including SF2/ASF, in a large nuclear complex of ~1 MDa molecular mass following size exclusion chromatography. Using coimmunoprecipitation experiments and in vitro pull-down assays, we mapped two distinct domains of RBM15B that are essential for its direct interaction with the N-terminal extension of CDK11 p110 , cyclin L2 and SR proteins such as 9G8 and SF2/ASF. Finally, we established that RBM15B is a functional competitor of the SR proteins SF2/ASF and 9G8, inhibits formation of the functional spliceosomal E complex and antagonizes the positive effect of the CDK11 p110 /cyclin L2 complex on splicing both in vitro and in vivo.
Here, we report the identification of the RNA Binding Motif protein RBM15B/OTT3 as a new CDK11 p110 binding partner that alters the effects of CDK11 on splicing. RBM15B was initially identified as a binding partner of the Epstein-Barr virus mRNA export factor and, more recently, as a co-factor of the nuclear export receptor NXF1. In this study, we found that RBM15B co-elutes with CDK11 p110 , cyclin L2 and SR proteins, including SF2/ASF, in a large nuclear complex of ~1 MDa molecular mass following size exclusion chromatography. Using coimmunoprecipitation experiments and in vitro pull-down assays, we mapped two distinct domains of RBM15B that are essential for its direct interaction with the N-terminal extension of CDK11 p110 , cyclin L2 and SR proteins such as 9G8 and SF2/ASF. Finally, we established that RBM15B is a functional competitor of the SR proteins SF2/ASF and 9G8, inhibits formation of the functional spliceosomal E complex and antagonizes the positive effect of the CDK11 p110 /cyclin L2 complex on splicing both in vitro and in vivo.
The human Cell division control 2 Like genes Cdc2L1 and Cdc2L2 encode two related protein kinases, denoted CDK11B and A, respectively, which are expressed as two predominant protein isoforms designated by their apparent molecular weight (p110 and p58 for the 110 and 58kDa isoforms) (1, 2) . Since current data indicate that the products of the two genes are functionally redundant, the term CDK11 will refer to products from both genes hereafter.
The CDK11 p110 and CDK11 p58 isoforms are produced from the same mRNAs through the use of an internal ribosome entry site (IRES) and two different AUG codons located in the coding sequence of the CDK11 p110 A and B mRNAs (3) . The cyclin L proteins are the regulatory partners of CDK11 p110 and CDK11 p58 (4) (5) (6) (7) (8) . These proteins are encoded by two genes, cyclin L1 and L2, which produce six distinct protein isoforms of various apparent molecular weights by alternative splicing (8) . The ~70 kDa cyclin L1 and L2 proteins contain an N-terminal cyclin box and a C-terminal arginine-serine rich (RS) domain very similar to that of splicing regulating SR proteins, while the short 20 to 35 kDa cyclin L1, L2 A/B and L1 proteins contain the cyclin box but lack the RS domain.
Expression of the large CDK11 p110 protein kinase isoforms is ubiquitous and constant throughout the cell cycle. CDK11 p110 protein is a nuclear protein present in two macromolecular complexes of 1-2 MDa and ~800 kDa that contain the cyclin L's, the largest subunit of RNAP II, the SSRP1 and SPT6 subunits of the transcription elongation factor FACT, CK2, and the Rap30 and Rap74 subunits of TFIIF (9) . Using the yeast two-hybrid strategy, we identified the splicing factors RNPS1 (10) and 9G8 (11) as the first direct CDK11 p110 binding partners. Both RNPS1 and 9G8 belong to the Serine-Arginine rich (SR) protein family, which stimulate excision of introns from pre-RNAs and regulate alternative splicing (12) . RNPS1 and 9G8 co-immunoprecipitate with CDK11 p110 and are phosphorylated by CK2 (13) and CDK11 p110 (11) , respectively. Taken together, these data suggested that CDK11 p110 was involved in splicing and/or transcription. In contrast, recent reports have demonstrated that the mitosisspecific CDK11 p58 protein is required for centrosome maturation, bipolar spindle formation and the maintenance of sister chromatid cohesion (14, 15) .
The involvement of CDK11 p110 in the regulation of transcription was first demonstrated by studies from our laboratory which established that anti-CDK11 p110 catalytic domain antibodies reduced the synthesis of RNA transcripts produced from both TATA-like and GC-rich promoters in standard in vitro transcription assays (9) .
More recently, CDK11 p110 was also identified as a positive regulator of hedgehog signaling in both fly and vertebrate cells (16, 17) , and as a modulator of the Wnt/-catenin signaling cascade (18) .
Several lines of evidence also confirmed the role of the CDK11 p110 /cyclin L complexes in pre-mRNA splicing. Immunodepletion of the CDK11 p110 kinase from nuclear extracts greatly reduced the in vitro splicing activity, while readdition of the CDK11 p110 immunoprecipitates rescued the splicing activity (11) . In addition, overexpression of CDK11 p110 in cultured cells increased in vivo splicing whereas overexpression of a catalytically inactive form of CDK11 p110 inhibited splicing (8) . Similarly, pre-incubation of nuclear extracts with purified cyclin L and L proteins bound to sepharose beads depletes the extract of in vitro splicing activity (8) . We also demonstrated the direct role of CDK11 p110 /cyclin L complexes in the regulation of pre-mRNA splicing by showing that ectopic expression of cyclin L's individually enhances in vivo splicing activity using a gal/luciferase reporter construct (8) . Moreover, enforced expression of cyclin L proteins alone or in combination with active or catalytically inactive CDK11 p110 strongly affects in vivo alternative splicing of an E1A mini-gene reporter construct (8) . In addition, others have shown that cyclin L1α is an immobile component of the splicing factor compartment (19) that is associated with hyperphosphorylated RNAPII (5) , and that cyclin L2 is a substrate of the nuclear protein kinase DYRK1A (7), which is a dual specificity protein kinase that phosphorylates several transcription factors and induces SR protein redistribution. Together, these data demonstrate that CDK11 p110 is part of macromolecular complexes regulating RNA synthesis at the interface of transcription and splicing, two tightly linked processes occurring concomitantly and reciprocally influencing each other. Recently, it was also shown that CDK11 and 9G8 interact with the eukaryotic initiation factor 3 subunit f (eIF3f) and together alter the 3' processing of the HIV-1 pre-mRNA (20) . The involvement of CDK11 p110 in RNA maturation most likely requires its indirect interaction with the nascent pre-RNAs via RNA binding proteins such as the SR proteins RNPS1 and 9G8, hnRNPs and other proteins containing RNA recognition motifs that remain to be identified Here, we report the identification of a new CDK11 p110 and cyclin L2 binding partner, the RNA Binding Motif protein RBM15B/OTT3. RBM15B was initially identified as a binding partner of the Epstein-Barr virus mRNA export factor (21) and more recently was found to be a co-factor of the nuclear export receptor NXF1 (22) . In the present study, we show that RBM15B is located in a nuclear macromolecular complex through its direct binding to CDK11 p110 /cyclin L complexes and the splicing factor 9G8. Using in vitro and in vivo splicing assays, we establish that RBM15B is a functional competitor of the SR proteins capable of inhibiting the formation of the spliceosomal E complex and antagonizing the positive effect of the CDK11 p110 /cyclin L2 complex on splicing.
EXPERIMENTAL PROCEDURES
Yeast two-hybrid screen _ The yeast two-hybrid screen was performed as previously described (10) using the full length CDK11B p110 (Cdc2L1) fused to the GAL4 DNA binding domain and cloned into the PAS1CYH2 plasmid and a human B-cell cDNA library subcloned into the pACT plasmid containing the GAL4 activation domain (kindly provided by Dr. S. Elledge).
Cell culture and transfection
_ HEK 293T and human foreskin fibroblasts (HFFs) were maintained in DMEM medium supplemented with 10% fetal calf serum (FCS) and 2% Lglutamine. Transfections of HEK 293T cells with expression vectors encoding CDK11 p110 , cyclins L1 and L2, 9G8, SF2/ASF and various RBM15B constructs were performed using the transfection reagents FuGene 6 (Roche), JetPEI (Qbiogene) or KLN47 (23) and cells were harvested 48h after transfection. Recombinant protein production _ His 6 -tagged (pFast Bac expression vector, Invitrogen) full length RBM15B and 9G8 (11) were expressed in Sf9 insect cells and purified using nickelnitrilotriacetic acid affinity column under native conditions according to the manufacturer's protocol (The QIAexpressionist TM , Qiagen). GST-RBM15B fusion proteins (Supplemental S8) were expressed in BL21 bacteria (Invitrogen) and purified with GSH-Sepharose TM 4B beads (Amersham Biosciences, Inc.) using the manufacturer's protocol. In vitro transcribed and translated CDK11, RBM15B and cyclin L2 proteins were produced using the TNT kit (Promega) and [S 35 ]-methionine (Perkin Elmer). Antibodies _ The CDK11 antibodies P2N100 (10), P1C (24) and cyclin L (8) antibodies have been described previously.
The RBM15B antibody was produced by immunization of rabbits with the purified GST-tagged NTerminal domain (amino acids 1 to 154, Supplemental S2B). Specific anti-RBM15B immunoglobulins were affinity purified using the GST N-Terminal domain covalently bound to sepharose 4B beads (Supplemental S2C,D Lysates were centrifuged at 14,000 rpm in a microcentrifuge for 20 min prior to incubation overnight with antibodies (500 g of lysates and 1 g of antibody) followed by a 2 h incubation with GammaBind plus sepharose beads (Amersham Biosciences, Inc.) at 4°C. Washes were performed 4 times with 1 ml of lysis buffer each time. Immunoblotting was performed as previously described (10) . GST pulldown assay _ Pull-down assay were performed by incubating GST-RBM15B fusion proteins (Supplemental S5) with [S 35 ]-methionine labeled IVTT products or total lysates of either non transfected HEK 293T to detect endogenous CDK11 p110 and SR proteins or transiently transfected to detect cyclins L1 and L2, SF2/ASF and 9G8. The lysis was performed using immunoprecipitation buffer and incubations were carried out for 2 hours at 4°C under gentle rotation. Beads were then washed 4 times with the same buffer prior to immunoblotting analysis or autoradiography of [S 35 ]-methionine labeled IVTT products.
In vitro splicing assay-The 32 P-labeled -globin pre-mRNA substrate was prepared by in vitro transcription using SP6 RNA polymerase and BamH1 linearized pSP64-HE6 plasmid as the template (25) . The HeLa nuclear (NE) extracts used for the in vitro splicing reactions were obtained from Promega.
In vitro splicing reactions were carried out in a final volume of 25 l with 25 ng of NE and 20 fmol of 32 Plabeled -globin pre-mRNA substrate followed by incubation at 30ºC for 4 h. The spliced RNA products were analyzed by electrophoresis on a denaturing 5.5% polyacrylamide, 7 M urea gel (25) . Statistical analysis was performed using the Statview software: the non parametric MannWhitney test was used and p<0.05 was considered significant.
For detection of functional spliceosomal complexes E, A, B and C, -globin RNA-protein complexes were resolved on native horizontal agarose minigels as previously reported (26) .
In vivo -galactosidase/luciferase splicing assay _ 293T cells were transfected using Fugene 6 (Roche Applied Science) as described by the manufacturer. The optimal amounts of DNA expression vectors for RBM15B, CDK11, cyclin L2, SF2/ASF and 9G8 used in the transfections were established in pilot experiments which were performed to optimize protein expression (data not shown). The cyclin L2 cDNA (1 g) containing an N-terminal FLAG tag was cloned into the pFlex vector. CDK11B p110 (Cdc2L1, 6 g) and CDK11B p110 DN (catalytically inactive due to mutation of amino acid D567 to N) (3 g) containing a C-terminal FLAG tag were in the pUHD 10-3 vector. N-terminal HA tagged RBM15B WT (0.5 g) was in the pCMV vector while RBM15B CORE [amino acids 1 to 609, (0.5 g)] and RBM15B CORE/NLS constructs [amino acids 1 to 609 + the putative NLS, (0.5 g)] were in the pcDNA 3.1 vector. All RBM15B truncated mutants are depicted in the Supplemental data S5, and contain an Nterminal HA tag. The C-Terminal 6His-tagged 9G8 and the N-terminal 6His-tagged SF2/ASF constructs (0.5 g) were in the pCEP4-E1A vector (gifts from Dr. W-Y Tarn). The splicing reporter vector pTN24 (a gift from Dr. I.C. Eperon) (27) was used (1 g) in all experiments. Cells were harvested 24 h after transfection for the enzymatic assays.
-galactosidase and luciferase activities were measured using the Dual-Light System (Applied Biosystems), Bright-Glo Luciferase Assay System (Promega) and Beta-Glo Assay System (Promega). All measurements were within the linear range that was established using luciferase and -galactosidase standards.
All samples were measured in quadruplicate, and 3 to 10 independent transfected cultures were assayed per data point. Immunoblot analyses of equal volume cell lysates were performed using anti-CDK11, -Cyclin L2, -RBM15B, -9G8 and -SF2/ASF polyclonal antibodies. 9G8 construct enforced expression was also detected by quantitative RT-PCR using 9G8 specific primers (5'GTTGGTAACCTGGGAACTGG3', (5'CGAATTCCACAAAGGCAAAT3') and SYBR green (Applied Biosystems). PCR samples were incubated for 10 min at (8) and available for free-download at : http://ftp.stjude.org/pub/inetdev/zhao_w/TwoSa mpleBlockRankTest.R.
RESULTS

The RNA Binding Motif protein RBM15B interacts with CDK11
p110 and is present in a large nuclear complex _ In order to identify new CDK11 p110 binding partners, a yeast two-hybrid screen was performed using the full length CDK11 p110 as bait and a human B-cell library. In addition to RNPS1, a known interactor of CDK11 p110 (10) , one of the proteins we identified in this screen was a partial cDNA (clone 33) that encoded the majority of the RNA Binding Motif 15B protein [RBM15B/OTT3 (One-Twenty Two 3)] but lacked the 5'end of the full length cDNA (Supplemental S1). RBM15B is an intronless gene that produces a 110 kDa protein (Supplemental S1C and S2C) which was initially identified through its physical interaction with the EB2 protein of the Epstein-Barr virus (EBV) (21) . RBM15B is highly similar to RBM15/OTT1 [(One-Twenty Two 1), supplemental S3] which was originally discovered as a fusion partner with the gene megakaryoblastic leukemia 1 (MKL1) in the translocation t(1;22)(p13;q13) associated with childhood acute megakaryocytic leukemia (28, 29) . RBM15/OTT1 and RBM15B proteins both contain three RNA Recognition Motifs (RRM) localized within the N-terminal half, a consensus nuclear localization signal and a Spen Paralog Ortholog (SPOC) C-terminal domain (Supplemental S1 and S3), which mediates interaction with the co-repressors of transcription SMRT (silencing mediator for retinoic and thyroid receptors) and NCoR (nuclear receptor corepressor).
Data from Hiriart et al. suggested that the RBM15B gene encodes two transcripts containing the same open reading frame but using alternative poly A signals: a major 3.5 kb short mRNA and a minor 6.6 kb variant including a 3.1 kb 3' UTR (21). In our experimental conditions, the 3.5 kb mRNA was the only transcript detected by northern blot in HFF and HepaRG cells (data not shown).
However, RT-PCR experiments confirmed the production of two RBM15B gene mRNA variants from mouse, rat and human in normal liver as well as HepaRG and HFF cell lines (Supplemental S1B).
To confirm the interaction between CDK11 p110 and RBM15B, transient transfections were performed in HEK293T using expression vectors encoding HA-and GFP-tagged RBM15B followed by immunoprecipitation (IP) of endogenous CDK11 p110 and immunoblotting of RBM15B using anti-HA and -GFP antibodies (Supplemental S2A). RBM15B was found in CDK11 p110 IP demonstrating that these two proteins co-immunoprecipitated. The reciprocal IPs using anti-HA and -GFP antibodies further confirmed the interaction between RMB15B and CDK11 p110 (Supplemental S2A). In addition, an anti-RBM15B specific antibody was raised ( Figure 1A and Supplemental S2B-D) to verify the interaction of endogenous CDK11 p110 and RBM15B. Endogenous CDK11 p110 and cyclin L proteins were immunoprecipitated from HEK293T cells and the specific anti-RBM15B antibody was used for immunoblotting. RBM15B associated with both CDK11 p110 and cyclin L protein IPs, but not in the control IP using total immunoglobulins ( Figure 1B) .
In situ detection of HA-RBM15B fusion protein and indirect immunofluorescence of endogenous RBM15B revealed a pattern of diffuse nucleoplasmic staining and an intense staining in large speckles (Supplemental S4 and S5B). Interestingly, we did not find any enrichment of RMB15B at the nuclear envelope as had been reported for the highly related protein RMB15/OTT1 (30) .
However, we observed a partial nuclear co-localization of RBM15B with both CDK11 p110 and the SR proteins SRp75, SRp55 and SRp20 (Supplemental S4). By western blotting, we found that expression of both CDK11 p110 and RBM15B was constant throughout the cell cycle of synchronized HFFs while there was a slight increase in CDK11 p110 levels during S and G2/M phases (supplemental S5A).
The nuclear colocalization of these two proteins was observed throughout interphase while they were evenly distributed in the cytoplasm during mitosis (Supplemental S5B).
Previously, we reported that CDK11 p110 and cyclin L's are present in two different macromolecular complexes containing transcription and splicing factors (8, 9, 11) . Our co-IP and nuclear co-localization of RBM15B with CDK11 p110 suggested that this RNA binding protein should also be present in these nuclear complexes. To confirm this hypothesis, HeLa nuclear extract was fractionated using Superose 6 size exclusion chromatography (Fig.  1C) . As expected, CDK11 p110 and cyclin L2 were detected in two large complexes of ~1MDa and ~500kDa and co-eluted with SR proteins including SF2/ASF. Interestingly, RBM15B was found predominately in a large complex of >1MDa indicating that only a fraction of CDK11 p110 was associated with RBM15B in a macromolecular nuclear complex.
Two distinct domains of RBM15B are involved in the binding to CDK11 p110 , cyclin L2 and 9G8 _
We next performed pull down assays using bacterially expressed GST-RBM15B fusion proteins in order to map the domain of interaction with CDK11 p110 . In the initial twohybrid screening we pulled out a partial RBM15B cDNA which lacked the N-terminal segment containing the first 154 amino acids (clone 33, see supplemental data S1 and S8) using CDK11 p110 as bait. This strongly suggested that the binding between RBM15B and CDK11 p110 involved a RBM15B motif downstream of the N-terminal domain. To confirm this hypothesis, we produced a series of recombinant proteins containing the N-terminal domain peptide, a protein lacking the N-terminal domain (clone 33) and full length RBM15B proteins fused to the GST to perform pull-down assays (Supplemental S8, Figure 2A ). These recombinant proteins, bound to sepharose beads, were incubated with HEK293T total cell extracts. The presence of interacting proteins including CDK11 p110 , SR proteins SRp75/55/35, and SF2/ASF was then detected by immunoblot analysis (Figure 2A , left panel). As expected, CDK11 p110 , SR proteins SRp75, SRp55 and SRp20 and SF2/ASF were found associated with the clone 33 and the full length RBM15B proteins, but, surprisingly, these proteins were also detected in the N-term RBM15B pull-down suggesting that the N-terminal domain of RBM15B contained another binding motif for CDK11 p110 . No proteins were detected in the negative control pull-down using the GST protein.
To further localize the interaction sites, we divided RBM15B in four distinct domains (Supplemental S8): the amino-terminal end (NTerm amino acids 1 to 154), the three RNA Recognitions Motifs (RRM, amino acids 141 to 489), the C-Terminal domain containing a putative Nuclear Localization Signal (CTerm/NLS, amino acids 490 to 720) and the SPOC domain at the very C-terminal end of the protein (amino acids 721 to 890).
In addition, we generated RBM15 fusion protein lacking only the SPOC domain (SPOC mutant amino acids 1-720). To demonstrate that two CDK11 p110 binding motifs were present in RBM15B we used these GST-fusion proteins to perform the pull-down assay (Figure 2A , right panel). CDK11 p110 , SR proteins SRp75/55/35 and SF2/ASF were found associated with the NTerm and C-Term/NLS domains and the SPOC mutant but not with the RRM domain. These data suggested that CDK11 p110 binding motifs were present in both the N-and C-Terminal domains of RBM15B and that the SPOC domain is dispensable for these interactions. Similar experiments were performed using RNase treated HEK293T cell extracts, which gave the same interactions indicating that binding of CDK11 p110 , SR proteins SRp75/55/35 and SF2/ASF to RBM15B was not mediated by RNA.
To further map the motifs of interaction in RBM15B, we generated additional GST-N-Term and C-Terminal fusion proteins of various lengths (Supplemental S8) that were used for pull-down assays to detect CDK11 p110 , Cyclins L1 and L2, 9G8, SF2/ASF and SR proteins p75/55/35 by immunoblot analysis ( Figure 2B ). No proteins were detected in the negative control pull-down using the GST protein alone, and only very minimal binding of cyclin L and SR proteins was seen in the shortest GST-NTerm RBM15B protein (5) while all of the proteins were bound to the other N-Term constructs (6 to 9, Figure 2B , left panel). Similarly, CDK11 p110 , Cyclins L1 and L2, 9G8, SF2/ASF and SR proteins p75/55/35 were not detected in the shortest three GST-C-Term-RBM15B proteins (11 to 13) but were all present in the longest truncation proteins (14 to 17, Figure 2B , right panel). These data confirmed that two domains of RBM15B are involved in the interaction with CDK11 p110 and its associated proteins, and suggested that the segments containing the amino acids 48 to 67 (C-Terminus of 6) and 585 to 607 (C-Terminus of 14) respectively localized within the NTerminal and C-Terminal domains of RBM15B (Figure 2 ) are essential either for the direct binding to CDK11 p110 or required for proper folding of the associated amino acids into the interaction domains.
These results also indicated that the peptide (amino acids 1 to 607) including the N-Term, RRM domains and amino acids 490 to 607 from the C-Terminal domain (Supplemental S8, RBM15B "core") is sufficient for the interaction with the splicing regulators such as SR proteins and CDK11 p110 /cyclin L complexes. In order to delineate the domain of CDK11 p110 required for its interaction with RBM15B we set up pull-down assays using the GST-RBM15B full length (FL) and in vitro transcribed and translated (IVTT) products of CDK11 p110 labeled with [S 35 ]-methionine ( Figure 3) . In vitro transcription and translation of CDK11A p110 cDNA generated nine products ( Figure 3A) , as previously observed (10), because of the initiation of translation from the eight internal AUG codons upstream of the CDK11 p58 AUG. Pull down assays using these IVTT reaction products showed that the full length CDK11
p110 proteins and at least 5 truncated IVTT products bound to the GST-RBM15B full length but not with the GST control protein ( Figure 3A) . In this experiment we did not detect the IVTT product of CDK11 p58 suggesting that RBM15B specifically binds to the N-Terminal domain of the CDK11 p110 form. In order to confirm this hypothesis and to determine whether RBM15B interacted directly with other proteins in the complex such as cyclin L2 and 9G8, we set up pull-down assays using the GST-RBM15B N-Term (9) and C-Term RBM15B (15) fusion proteins and in vitro transcribed and translated (IVTT) products of CDK11 p110 , the N-Terminal domain of CDK11 p110 upstream of the CDK11 p58 sequence, CDK11 p58 , Cyclin L2 and bacterially produced recombinant 9G8 ( Figure 3B ). Full length CDK11 p110 IVTT product interacted with the CTerminal domain of RBM15B but, unexpectedly, it did not bind the N-Terminal motif in contrast to the interaction data obtained from the pull down assays performed with total cell lysates ( Figure 2B) . Similarly, the NTerminal CDK11 p110 IVTT product was found associated with the C-Terminal domain of RBM15B and not the N-Terminal motif, while CDK11 p58 IVTT did not bind either of the two RBM15B recombinant peptides. We also found that cyclin L2 IVTT protein interacted with both N-and C-Terminal domains of RBM15B while recombinant 9G8 bound only to the RBM15B C-Terminal motif.
These data indicated that only the N-Terminal extension of CDK11 p110 interacts with the C-Terminal domain of RBM15B while the cyclin L2 binds to both domains of RBM15B and potentially bridged CDK11 p110 to the N-Terminal domain of RBM15B in the total cell lysate assays ( Figure  2B ). RBM15B inhibits pre-mRNA splicing in vitro _ Since Hiriart et al. (21) reported that RBM15B affected the alternative splicing of a -thalassemia reporter pre-RNA (containing a Gto-A transition at position 1 of intron 1 that results in the usage of three cryptic 5'-splice sites and expression of three mRNA variants by alternative splicing) in transfected cells indicating that the RBM15B protein could regulate pre-mRNA splicing, we investigated whether RBM15B could affect splicing in vitro using the radiolabeled human -globin pre-RNA, HeLa nuclear extract (NE) and recombinant GST-fusion RBM15B proteins (Figure 4) . Addition of increasing amounts of GST-RBM15B full length, GST-RBM15B lacking the carboxy-terminal SPOC domain (1 or SPOC: amino acids 1 to 720) or the truncated GST-RBM15B core (3 mutant) proteins resulted in dose dependent decrease in the ability of the NE to catalyze the excision of the pre-RNA intron (Figure 4 ) while addition of GST alone did not affect the splicing rate. Supplementation of splicing assays with the NTerm domain (9: amino acids 1 to 159) had no significant effect, while GST-RRM (10) and GST-C-Term/NLS (17) domains, separately, showed a ~40 to 60% decrease in the amount of spliced -globin RNA. Furthermore, addition of the GST-RRM+C-Term/NLS domains (2) resulted in a strong inhibition of -globin splicing (Figure 4 ) demonstrating that the most potent inhibitory effects were observed with the RRM associated with the N-and/or Cterminal/NLS domains. Together, these results demonstrate that RBM15B is a strong inhibitor of pre-mRNA splicing.
RBM15B inhibits pre-mRNA splicing in vivo.
The double -galactosidase/luciferase reporter system, designed to measure splicing activity in vivo (27), was next employed to ascertain whether RBM15B full length or mutants affect splicing in vivo, and to see which regions of RBM15B are important for its ability to regulate splicing. Unspliced transcripts produced by transiently transfecting the pTN24 construct into HEK293T cells yields a protein with only the -galactosidase activity, whereas properly spliced intronless mRNAs are translated into a fusion protein with both -galactosidase and luciferase activities. Thus, the ratio of luciferase to -galactosidase activity in the cell lysate allows us to measure the proportion of spliced mRNA. Co-transfection of RBM15B expression constructs was conducted to evaluate the effects of RBM15B on splicing in comparison to cotransfection of pTN24 with control empty expression vector (data was normalized to baseline control activity seen upon co-transfection with the empty vector which was arbitrarily set as 1).
Titration experiments showed that transfections performed using 0.5 g of RBM15B full length and mutant expression vector plasmid DNAs did not significantly affect the -galactosidase expression while higher amounts (>1g) significantly decreased expression (data not shown). Ectopic expression of full length RBM15B (WT), the GST-RBM15B protein lacking the SPOC domain (SPOC: 1), the RBM15B Core (Δ3) or the core peptide plus an exogenous nuclear localization domain (RBM15B Core/NLS: Δ4) all significantly repressed the relative splicing activity compared to the control cells transfected with empty expression vectors ( Figure 5A ). Conversely, enforced expression of the RBM15B-N-Term (9: amino acids 1 to 154) showed no effect on splicing ( Figure 5A ). For these experiments, protein expression was verified by immunoblotting ( Figure 5B ). As seen in the in vitro splicing assays, the RRM domains were necessary for inhibition of splicing. Thus, expression of RBM15B WT or the truncated RBM15B constructs containing the RRM domains inhibit excision of the intron from the -galactosidase/luciferase reporter premRNA in vivo. In order to determine whether inhibition of splicing by RBM15B was specific to -globin or if RBM15B could affect splicing of other pre-mRNAs, we used an in vivo E1A minigene reporter system (Supplemental S6) that encodes an unspliced RNA and five splice variants (13, 12, 11, 10 and 9S). In these experiments, HepaRG cells were transiently transfected with 2 g of E1A encoding vector, increasing amounts of RBM15B expression vectors and appropriate amounts of empty vector to reach equal concentrations of plasmid in all conditions (Supplemental S6). RBM15B expression was verified by immunoblotting (Supplemental S2C).
RT-PCR and gel electrophoresis were performed to detect E1A RNAs (Supplemental S6B). We found that enforced expression of RBM15B led to the increase in unspliced E1A pre-RNA content and a decrease in the levels of the 12 and 9S splice variants. Interestingly, the amounts of the 13 and 10S forms were not significantly affected by expression of RBM15B while the 11S variant was not detected in these cells. Together, these in vivo data indicate that RBM15B most likely affects the overall exon splicing and confirm that RBM15B affects alternative splicing (21) .
RBM15B inhibits splicing by competition with SR proteins _
The double -galactosidase/luciferase reporter system was also used to determine whether RBM15B could antagonize the stimulation of splicing induced by the SR proteins 9G8 and SF2/ASF. Expression vectors encoding RBM15B, 9G8, SF2/ASF and control expression vectors were co-transfected with pTN24. As expected, a strong increase in the ratio of luciferase to -galactosidase activity was observed in cells expressing 9G8 and/or SF2/ASF ( Figure 6A ). Consistent with the results shown above, ectopic expression of RBM15B alone decreased splicing activity.
Importantly, the relative splicing activity was significantly reduced in cells coexpressing RBM15B with 9G8 and/or SF2/ASF compared to cells expressing the SR proteins alone ( Figure 6A ) demonstrating that RBM15B was indeed capable of antagonizing the positive effects of SR proteins on splicing. For these experiments, protein expression was verified by immunoblot ( Figure 6B ) and the overall increase in 9G8 expression was confirmed by quantitative RT-PCR ( Figure 6C ). To further demonstrate that RBM15B was a direct competitor of SR proteins, we performed in vitro splicing assays using the -globin construct and S100 cell extract supplemented with recombinant SF2/ASF and 9G8 ( Figure 6D ). S100 cytoplasmic extracts contain components of the spliceosome but lack the SR proteins needed for recruiting the factors required to catalyze the intron excision of the -globin pre-RNA and to generate the spliced product ( Figure  6D, lane 2) . Addition of 50 ng (~2 pmol) of recombinant purified SF2/ASF or 9G8 to the S100 extract allows the splicing reaction to occur (lane 3 and 7). Importantly, when increasing amounts of GST-RBM15B were added to the S100 supplemented with SF2/ASF or 9G8, a dose-dependent inhibition of the splicing process was observed (lanes 4-6 and 8-10) while addition of control GST did not affect the amount of spliced product (lanes 3 and 7) .
Together, these data demonstrate that RBM15B is able to inhibit SF2/ASF-and 9G8-mediated splicing indicating a direct competition between the positive splicing factors SF2/ASF and 9G8 and the splicing inhibitor RBM15B. Importantly, these in vitro data also allow us to conclude that RMB15B directly affects splicing regardless of its effect on RNA export (30) , since detection of the spliced product in this assay does not require transport of the RNA.
To further elucidate whether RBM15B inhibited spliceosomal assembly, the formation of spliceosomal complexes (E, A, B and C complexes) corresponding the sequential recruitment of the spliceosome subunits (26) was investigated using the -globin pre-RNA and nuclear extract supplemented with recombinant GST and GST-RBM15B proteins ( Figure 6E and Supplemental S7B). Without any recombinant proteins added, we detected the sequential formation of E ( Figure 6E ), A, B and C (Supplemental S7B) complexes. Addition of 5 pmol of GST did not affect formation of spliceosomal complexes while increasing amounts (0.5 to 5 pmol) of RBM15B strongly prevented formation of all complexes demonstrating that RBM15B inhibited the first step of spliceosome assembly, the formation of the E complex corresponding to the recruitment of the U1snRNP onto pre-RNAs. RBM15B antagonizes the positive effect of the CDK11 p110 /cyclin L2 complex on pre-mRNA splicing _ We have recently established that CDK11 p110 interacts physically and functionally with cyclin L proteins to regulate splicing (8) .
We also showed that ectopic expression of CDK11 p110 and cyclin L's individually enhances splicing activity, and, importantly, that coexpression of CDK11 p110 and cyclin L2 resulted in a greater splicing activity than either of these two proteins alone (8) . Because RBM15B interacts with and is found in a nuclear complex with CDK11 and cyclin L2, we next addressed the question of whether RBM15B could modulate splicing promoted by the CDK11 p110 and cyclin L2 complex. Using the same in vivo assay shown in Figures 5 and 6 , splicing activity was measured following coexpression of wild-type or kinase-dead CDK11 p110 with cyclin L2 and RBM15B ( Figure 7B ).
Each protein was expressed individually and in combination in order to be able to compare the effects of individual expression and combined co-expression on the relative splicing activities. In these experimental conditions, the total amount of plasmid DNA in the transfection was equalized by addition of the appropriate empty vector. Protein expression levels for the "paired" transfections are shown in Figure 7A . As expected, individual expression of CDK11 p110 WT and cyclin L2 and their coexpression enhanced splicing while expression of RBM15B and kinase-dead CDK11 p110 (DN mutant) alone or in combination with cyclin L2 repressed splicing. Finally, co-expression of RBM15B with CDK11 p110 WT and/or cyclin L2 inhibited splicing activities by 4 to 5-fold compared to the conditions without enforced expression of RBM15B. Thus, the protein RBM15B antagonizes the positive effect of the CDK11 p110 /cyclin L2 complex on splicing in vivo.
DISCUSSION
Previous data from our laboratory demonstrated that CDK11 p110 and its regulatory cyclin L subunits interact with several splicing factors and regulators of transcription to form at least two large macromolecular complexes involved in the regulation of transcription and RNA splicing (8, 9, 11 p110 , the cyclins L1 and L2 and SR proteins including SF2/ASF in a large nuclear complex of ~1 MDa molecular mass following size exclusion chromatography. Using in vitro pull-down assays, we mapped two distinct domains of RBM15B responsible for its direct interaction with the N-terminal extension of CDK11 p110 as well as the cyclin L isoforms and the splicing factor 9G8.
RBM15B/OTT3 is a member of the Spen (Split end) family of proteins (31) . This family includes huSHARP (SMRT/HDAC1-associated repressor protein), muMINT (Msx2 interacting nuclear target), RBM15/OTT1 and RBM15B/OTT3 (Supplemental S3). RBM15B (21) is the most highly related to RBM15/OTT1 [One-Twenty Two 1, (Supplemental S3)], which was originally discovered as a fusion partner with the gene megakaryoblastic leukemia 1 (MKL1) in the translocation t(1;22)(p13;q13) associated with childhood acute megakaryocytic leukemia (28, 29) . All of these proteins contain three highly conserved N-terminal RNA binding motifs, suggesting they play a role in mRNA synthesis, processing or export, and a C-terminal SPOC (Spen paralog and ortholog C-terminal) domain, which mediates interaction with the corepressors of transcription SMRT (silencing mediator for retinoic and thyroid receptors) and NCoR (nuclear receptor corepressor). SHARP binds these corepressors with a high affinity and strongly represses transcription (32, 33) . Repression of transcription mediated by SHARP and its associated co-repressors SMRT and NCoR (32, 33 ) is thought to involve modification of chromatin structure by recruitment of histone deacetylases (HDACs), especially HDAC3, that directly bind to both corepressors SMRT and NCoR (34) . RBM15/OTT1 and RBM15B also interact with each other (22) strongly suggesting their involvement in the same biochemical processes. Importantly, Spen proteins also function in several signaling cascades including Mitogen-Activated Protein Kinase (MAPK) (35) , Wnt (36), Notch (37), Hox10 (38) and epidermal growth factor receptor (EGFR) (39) .
In the first report investigating the function of RBM15/OTT1 and RBM15B their involvement in the regulation of transcription was not clear since neither of these proteins strongly represses transcription of reporter constructs in transfected cells (21) . In agreement, the SPOC domain of these proteins interacts weakly with SMRT, and they lack the domains of SHARP [nuclear receptor interacting domain (RID) and RBP-J interaction (RBPID)] that target SHARP to specific promoters to repress transcription (33) . However, these two proteins do interact with HDAC3, like the other family members (40) . In addition, recent data indicated that RBM15 and the RMB15-MKL1 fusion protein can modulate the levels of multiple mRNAs, including the proto-oncogene c-myc (41), although this study did not conclusively establish that these changes in gene expression resulted from the direct effects of RBM15 or RBM15-MKL-1 on transcription (41) . Taken together these recent data suggest that the two Spen family members RBM15/OTT1 and RBM15B may play some role in the regulation of transcription.
In contrast to the inconclusive data on the role of RBM15/OTT1 and RBM15B in transcription, existing data and the studies present herein demonstrate that RBM15/OTT1 and RBM15B are involved in RNA splicing and/or mRNA export. The conclusion that RBM15/OTT1 plays a role in mRNA export is based on studies showing that RBM15/OTT1 binds to the RNA transport element (RTE) and the mRNA export factors NFX1 (42) . Furthermore, recent data by Zolotukhin et al (30) support the hypothesis that RBM15/OTT1 promotes the recognition of spliced RNA-NFX1 complexes by the RNA helicase Dbp5, thereby contributing to efficient messenger ribonucleoprotein complex (mRNP) export through the nuclear pore complex (NPC). Similarly, RBM15B associates with NFX1 and contributes to mRNA export (30) . In fact, RBM15B was initially isolated as an interactor of the Epstein-Barr virus early protein EB2, a viral protein that exhibits properties of an mRNA export factor (43) .
Of particular relevance to our study, Hiriart et al (21) demonstrated that RBM15B/OTT3 regulates alternative splicing.
The fact that RBM15B is part of a large nuclear complex containing CDK11 p110 /cyclin L complexes, as well as several SR proteins, strongly reinforced the hypothesis that this RNA binding protein could also be involved in RNA maturation upstream of its involvement in export. Here we used in vitro and in vivo splicing assays to further investigate the involvement of RBM15B in constitutive exon splicing. We demonstrate for the first time that recombinant RBM15B/OTT3 added to nuclear extract strongly inhibits in vitro splicing of a human -globin construct. Similarly, enforced expression of RBM15B in transiently transfected mammalian cells led to a significant reduction of pre-RNA reporter systems that monitor constitutive splicing adding to the conclusion that RBM15B is a potent inhibitor of splicing. RBM15B possesses three RNA Recognition Motifs very similar to hnRNPs (31) . Most hnRNPs inhibit splicing by competition with SR proteins (12, 44) . While SR proteins bound to exonic or intronic splicing enhancer sequences of the pre-RNA generally promote recruitment of the spliceosome subunits, many hnRNPs bind to exonic or intronic splicing silencer sequences and inhibit spliceosome activation or cancel the positive effects of SR proteins on splicing (12, 44 ). Thus, we tested whether RBM15B was able to antagonize the positive effect of SR proteins on splicing. For these studies we performed in vitro experiments using S100 cyotplasmic extract, which is unable to catalyze in vitro splicing of the -globin reporter pre-RNA unless it is supplemented with SR proteins. In our assay, S100 extract was supplemented with the recombinant SF2/ASF and 9G8 SR proteins and addition of recombinant RBM15B decreased splicing mediated by both SF2/ASF and 9G8.
Moreover, using the -galactosidase/luciferase reporter system we confirmed the RBM15B inhibited splicing promoted by SF2/ASF and 9G8 in transfected cells. These data led us to determine whether RBM15B could affect the assembly of spliceosome subunits. Using the -globin in vitro splicing assay we showed that RBM15B prevented formation of the E spliceosomal complex, the first step of the assembly. Altogether these data indicate that RBM15B negatively regulates splicing by acting as a functional competitor of SR proteins.
Since we previously established that CDK11 p110 /cyclin L complexes enhance splicing (8), we also investigated whether RBM15B could negatively regulate the splicing mediated by CDK11 p110 and/or cyclin L proteins. Using -galatosidase/luciferase reporter in vivo splicing assays, we established that RBM15B antagonizes the positive effect on splicing of CDK11 p110 or cyclin L2 expressed separately or co-expressed in 293T cells. Thus, the large molecular complex containing CDK11 p110 either contains both positive and negative regulators of splicing and/or CDK11 p110 forms multiple complexes alternatively containing either SR proteins or RBM15B. Based on our pull down and co-IP experiments using CDK11, RBM15B and SR proteins, we favor the hypothesis that both positive and negative regulators of splicing co-exist in CDK11 p110 protein complexes, but we cannot rule out the possibility of multiple complexes. The synthesis of mRNA is indeed a highly dynamic process that recruits multiple positive and negative factors at different steps of transcription, elongation and splicing. In addition, cyclin L's also bind to CDK12 (45) and CDK13 (46, 47) to regulate splicing. It thus appears important to further investigate whether these other CDKs can also bind RBM15B via their cyclin L partners. The multiple potential interactions between CDKs, cyclin L's, SR proteins and hnRNPs, such as RBM15B, also raises the questions of relevance of these complexes in the regulation of the multiple processes occurring during mRNA synthesis. Beyond the description of these interactions, a major challenge remains to decipher how the CDKs affect pre-mRNA processing by the identification of specific phosphorylation substrates and by characterization of responses to various signaling pathways. . GST-pull down assays were performed using a series of GST-RBM15B fusion peptides (Supplemental S8) incubated with lysates from HEK293T cells transfected with expression vectors for Cyclins L1, L2, 9G8 and SF2/ASF, or lysates of non transfected cells for CDK11 p110 and SR proteins SRp75, SRp55 and SRp35 binding assays . Detection of proteins bound to GST and GST-RBM15B beads was performed using specific antibodies. Panel A, GST pull-down assays with the RBM15B full length (FL), N-TERM (9, amino acid 1 to 154), clone 33 (amino acids 249 to 890), RRM (10, amino acids 141 to 489), C-TERM/NLS (17, amino acids 490 to 720), and SPOC (1, amino acids 1 to 720). GST pull down using recombinant GST-RBM15B mutants 9, 10, 17 and 1 were performed in absence (-RNase) or presence (+RNase) of RNase (Benzonase® 20U/ml, Merck). Panel B, GST pull-down assays with deletion constructs for the N-TERM (5 to 9) and C-TERM/NLS regions (11 to 17) of RBM15B and mapping of the two CDK11/cyclin L binding domains. , cyclin L2 and 9G8 A, [S 35 ]-methionine labeled CDK11 p110 IVTT products were generated from translation initiating at several internal AUG codons indicated as their corresponding methionines (1 to 9). Methionine (met) 1 corresponds to the translation start for full length CDK11 p110 while met 9 is the translation start for the CDK11 p58 isoform. The poly-glutamine (Poly E) domain of CDK11 p110 is located between methionines 8 and 9. The GST pull down assay was performed using CDK11 p110 IVTT products incubated with GST-RBM15B full length (FL) and GST as control. B, pull-down assay using the GST-RBM15B N-Term (9) and C-Term RBM15B (15) fusion proteins incubated with [S 35 ]-methionine labeled IVTT products of CDK11 p110 , the N-Term domain of CDK11 p110 upstream of the sequence of CDK11 p58 , CDK11 p58 , Cyclin L2 and bacterially produced recombinant 9G8 protein. IVTT products were visualized by autoradiography while 9G8 was detected by immunoblotting.
Figure 4
RBM15B inhibits in vitro splicing of the -globin pre-RNA. HeLa NE was used for an in vitro splicing assay using the pre-RNA of the human -globin gene as a substrate. Five well characterized -globin RNA species with different electrophoretic mobilities (25) are represented : white and black rectangles indicate exons 1 and 2, respectively, while the line represents the intron separating the two exons. The splicing reaction was supplemented with GST (5 pmol/25 l splicing reaction) and increasing concentrations (0.5, 2.5 and 5 pmol/splicing reaction) of GST-RBM15B fusion proteins (Supplemental S5): full length (FL), RBM15B core (3), SPOC (1), N-TERM (9), RRM (10), C-TERM/NLS (17) and RRM+C-TERM/NLS (2). The data in the chart represent the mean ± SD of three independent experiments. Statistical analysis was done using non parametric Mann-Whtiney test: *p<0.05 vs GST control condition.
Figure 5
RBM15B inhibits in vivo splicing of the -galactosidase/luciferase reporter system. Expression constructs for RBM15B wild type (WT), N-TERM, SPOC, Core and Core/NLS and empty vector were transiently co-transfected into HEK293T cells with the pTN24 splicing reporter plasmid for 24 h. RBM15B expression vector was titered to determine the optimal amount for in vivo splicing assays (0.5 g). A, Relative splicing activities were calculated using the ratios of luciferase to -galactosidase activities with the activity of the control cells transfected with empty expression vectors (Control Vectors) set at 1. The results shown represent 3-6 independent transfection experiments in which one plate was transfected, and each lysate was measured in quadruplicate. The error bars represent the standard error of the mean. * denotes p < 0.001 compared with empty vector calculated using a nonparametric rank model. B, Cell lysates were analyzed by immunoblotting for expression of RBM15B proteins (anti-RBM15B antibody). Relative protein loading was confirmed by immunoblotting with anti-actin antibody.
Figure 6
RBM15B suppresses in vivo and in vitro splicing mediated by the SR protein SF2/ASF. Expression constructs for RBM15B wild type (WT) and the SR proteins SF2/ASF or 9G8 were transiently co-transfected with the splicing reporter plasmid pTN24 for 24 h. A, Relative splicing activities were calculated using the ratios of luciferase to -galactosidase activities with the activity of the control cells transfected with empty expression vectors (Control Vectors) set at 1. The results shown represent 6 independent transfection experiments in which one plate was transfected, and each lysate was measured in quadruplicate. The error bars represent the standard error of the mean. Statistically significant comparison data is indicated by the following symbols: *, p < 0.0007 for comparisons to control vectors; +, p < 0.01 for RBM15B to RBM15B/SF2 and RBM15B/9G8/SF2; #, p < 0.01 for 9G8 to 9G8/SF2, RBM15B/9G8 and RBM15B/9G8/SF2; ^, p < 0.01 for SF2 to 9G8/SF2, RBM15B/SF2 and RBM15B/9G8/SF2; and $, p < 0.01 9G8/SF2 to RBM15B/9G8/SF2. B, Cell lysates were analyzed by immunoblotting for expression of the exogenous and endogenous proteins. *6His-tagged 9G8 was detected by immunoprecipitation from cell lysates using Ni-NTA agarose (Qiagen), and immunoblotting with anti-9G8-ZnK polyclonal antibody. Actin detection demonstrated that equal lysate volume loading resulted in comparable total protein levels. C, Overall enforced expression of 9G8 was confirmed by quantitative RT-PCR. D, Cytoplasmic S100 cell extract was used for an in vitro splicing assay using the pre-RNA of the human -globin gene as substrate. S100 extract does not catalyze excision of the -globin intron without the addition of SR proteins. The accumulation of the mature -globin spliced product in the presence of HeLa nuclear extract (NE, lane 1) is not observed using the S100 fraction alone (lane 2). Addition of 2 pmol/splicing reaction of recombinant SF2/ASF (lane 3) or 9G8 (lane 7) proteins to the S100 fraction is sufficient to activate splicing of the -globin pre-RNA. Increasing amounts (0.5, 2.5 and 5 pmol/splicing reaction) of GST-RBM15B FL protein inhibited the SF2/ASF-(lanes 4 to 6) and the 9G8-mediated splicing (lanes 8-10), while addition of GST alone (5 pmol/splicing reaction, lanes 3 and 7) had no effect. In vitro splicing assays using SF2/ASF were performed with HeLa nuclear extract produced according Dr. Mayeda (48) , while splicing reactions with 9G8 were performed using HelaScribe® nuclear extract (Promega). These two extracts differed in splicing activities (Supplemental S7A). Higher activity was observed in the HeLaScribe as demonstrated by the low abundance of the intermediate splicing product (intron-exon 2). However, RBM15B inhibited splicing with both extracts. E, Detection of the spliceosomal complex E was perfomed using the -globin substrate and native horizontal agarose mini-gels. The ATP-independent spliceosomal complex E was detected after a 40 minute incubation of the -globin pre-RNA with HeLa nuclear extract at 30°C (lane 2). At the temperature of 0°C (lane 1) this complex did not form. Addition of increasing amounts (0.5, 2.5 and 5 pmol/splicing reaction) of GST-RBM15B FL protein inhibited formation of the E complex at 30°C while 5 pmoles of GST did not affect this splicing step. The H complex is a non-specific complex resulting from binding of hnRNP proteins to preRNAs. 
